Purpose: To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers. Methods: This study included 550 subjects (203 HC, 221 relapsing-remitting MS (RR-MS), 126 progressive MS (P-MS)). A complete lipid profile including total cholesterol (TC); high-density lipoproteincholesterol (HDL-C); low-density lipoprotein-cholesterol (LDL-C); apolipoproteins (Apo) A1, A2, B, and E; C-reactive protein (CRP); 24-hydroxycholesterol (HC); 25-HC; 27-HC; 7α-HC; and 7-ketocholesterol (KC) was obtained. Lipoprotein particle sizing by proton nuclear magnetic resonance (H 1 NMR) was available for 432 subjects. Results: The levels of 24-HC, 27-HC, and 7α-HC (all p < 0.015) were lower in MS compared to HC, and 7-KC was higher in P-MS compared to RR-MS (p < 0.001). TC, LDL-C, and ApoB were associated with higher levels of all oxysterols (all p < 0.05) in HC. In MS, LDL-C was associated with higher levels of 24-HC, 25-HC, 7-KC, and 7α-HC (all p < 0.05), while TC and ApoB were associated with increased levels of all oxysterols (all p < 0.005). Conclusion: The findings of lower 24-HC, 27-HC, and 7α-HC in MS compared to HC and higher 7-KC in P-MS compared to RR-MS indicate that the oxysterol network is disrupted in MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease characterized by demyelination in the central nervous system (CNS). Cholesterol is required for myelin structure and proper functioning of neuronal, vascular, and immune cells in the CNS. About 25% of cholesterol in the human body is found in the brain. The brain is dependent on de novo cholesterol synthesis from acetyl-coA because lipoprotein cholesterol from the peripheral circulation does not cross the blood-brain barrier (BBB). In our previous work, we have shown that higher levels of high-density lipoprotein-cholesterol (HDL-C) are associated with lower measures of BBB breakdown, assessed using cerebrospinal fluid (CSF) measures of macromolecules, and CNS inflammation. 1 Additionally, we found a significant association between low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels and inflammatory magnetic resonance imaging (MRI) activity measures, 2 as well as worsening disability measured using the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS) (10) (11) (12) (13) . However, the mechanisms underlying the associations of cholesterol biomarkers with disease progression in MS are unknown.
Oxysterols are oxygenated cholesterol metabolites that can cross the BBB and are, therefore, thought to play an important role in brain cholesterol regulation. [3] [4] [5] Oxysterols such as 24-HC, 27-HC, and 25-HC are endogenous agonists for the liver X receptor (LXR), a nuclear receptor involved in regulating metabolic and immune processes. 6 24-HC is exclusively produced in the brain via cytochrome P450 (CYP) 46A1 in neurons and is able to traverse the BBB; its plasma levels reflect neuronal loss and brain atrophy. 4, 5 27-HC, produced by CYP27A1, also has the ability to cross the BBB and is the most abundant oxysterol in the circulation. 5, 7 Both 7α-HC, formed via CYP7A, and 7-KC, formed by auto-oxidation of cholesterol, stimulate an inflammatory phenotype in human endothelial cells. 25 -HC, which is produced by macrophages, has inflammatory and antiviral effects. 8 Thus, oxysterols regulate cholesterol homeostasis, enhance inflammatory reactions, contribute to endothelial cell dysfunction, and exhibit pro-oxidant effects. 7, 9 There is now increasing evidence that oxysterols play a role in the pathophysiological processes mediating MS disease progression. 10 Based on these findings, our working hypothesis was that levels of oxysterols, particularly 24-HC, 25-HC, 27-HC, 7-KC, and 7α-HC, would be altered by MS disease course. The goals of this translational study are to identify the demographic, clinical, and cholesterol biomarker covariates associated with oxysterol profiles in MS patients.
Methods

Study population
Study setting. This is a single-center, prospective observational study.
Clinical study design. Samples and clinical data from an ongoing prospective study of clinical, genetic, and environmental risk factors in MS at the MS Center of the State University of New York at Buffalo were used. The study included patients with MS, clinically isolated syndrome (CIS), healthy controls (HCs), and controls with other neurological diseases (OND).
Patients and controls underwent neurological and MRI examinations, provided blood samples, and responded to a structured questionnaire administered in-person. 11 Body mass index (BMI) was derived from the patient's height and weight. Smoking status was obtained from patient responses to the structured questionnaire.
Informed consent. The University at Buffalo Human Subjects Institutional Review Board approved the study protocol, and all participants provided written informed consent.
Inclusion and exclusion criteria. Patients with the following characteristics: 18-65 years of age, children younger than 18 years, adults over 65 years of age, CIS, neuromyelitis optica, or OND were excluded from this substudy.
Oxysterol assays
Oxysterols (7α-HC, 24-HC, 25-HC, 27-HC, 7-KC) were determined in EDTA plasma samples by liquid chromatography-selected ion monitoring-stable isotope dilution-atmospheric pressure chemical ionization-mass spectroscopy (LC-SIM-SID-APCI-MS) as previously described. 12 Total sterols and oxysterols were released from steryl esters by cold saponification (0.35M KOH in ethanol containing 0.05% butylated hydroxytoluene (BHT) and under argon atmosphere), neutralized, and extracted on HyperSep C-18 solid-phase extraction tubes before being concentrated and injected into a reversed phase, C-18 LC system using a gradient mobile phase of methanol and water. The Shimadzu We, and others, 13 have found that oxysterol analytes are stable at −80°C storage. The mild room temperature saponification in the presence of BHT under argon ameliorated auto-oxidation of cholesterol or degradation of preformed oxysterols, particularly 7-KC. This method successfully resolves the most critical isomeric pairs including separation of 24-HC from 25-HC, 7α-HC from 7β-HC, and 7-KC from 7α-hydroxy cholesten-3-one. 12 The assay was systematically validated in accordance with the Food and Drug Administration (FDA) guidance for bioanalytical methods. The coefficient of variation (CV) of each oxysterol analyte was ⩽8.7%.
Lipids and apolipoproteins
EDTA plasma samples for lipid and apolipoprotein analyses were obtained in the non-fasted state. Our previously published 14 methods for lipid and apolipoprotein analyses were used. Analysts were blinded to the clinical status of samples.
TC, HDL-C, phospholipids, and triglycerides were measured with diagnostic reagent kits from Sekisui Diagnostics (Lexington, MA) an ABX Pentra 400 (Horiba Instruments, Irvine, CA) automated chemistry analyzer. LDL-C was obtained from the Friedewald equation. 15 Immunoturbidometric diagnostic kits (Kamiya Biomedical, Thousand Oaks, CA) were used for the apolipoprotein (AI, AII, B, and E) and highsensitivity C-reactive protein (CRP) assays. The CV of these assays is <5%.
Lipoprotein particle size analysis Lipoprotein particle number and size were measured using proton nuclear magnetic resonance (H 1 NMR) spectroscopy (LipoScience, Raleigh, NC). The measured amplitudes of the lipid methyl group NMR signals are used to calculate particle concentration, and the particles sizes are the sum of the diameter of each subclass multiplied by the relative mass percentages from the NMR signals.
Data analysis SPSS (IBM, Inc., Armonk, NY; version 22.0) statistical program was used. In view of the multiple testing, the Benjamini-Hochberg 16 method was used to assess significance with a target false discovery rate of q ⩽ 0.05. The tables and results summarize the raw, unadjusted p-values. Adjusted p-values (q-values) are shown only for variables with unadjusted p-values ⩽0.05. Secondary progressive (SP) and primary progressive (PP) MS were categorized as progressive MS (P-MS). 17 The Mann-Whitney test was used to assess differences in oxysterol levels (24-HC, 25-HC, 27-HC, 7α-HC, and 7-KC) for dichotomous variables, for example, between HC versus MS patients, relapsingremitting MS (RR-MS) versus P-MS, and MS patients with borderline or high cholesterol (defined as TC >200 mg/dL) versus desirable cholesterol levels (TC ⩽200 mg/dL).
The associations of oxysterol variables (24-HC, 25-HC, 27-HC, 7α-HC, and 7-KC) with lipid profile variables (HDL-C, LDL-C, TC, ApoA-I, ApoA-II, ApoB, ApoE, and CRP) were investigated using linear regression analyses where the lipid variable of interest was the dependent variable, and age, gender, BMI, and quartiles of 24-HC, 25-HC, 27-HC, 7α-HC, or 7-KC were treated as covariates.
The Kruskal-Wallis test was used to assess whether oxysterol levels were significantly different between patients receiving interferon, glatiramer acetate, or no current treatment. A Mann-Whitney test was used to assess whether oxysterols differed between patients who were presently receiving interferon and those who were not currently on an interferon regimen.
Results
Demographic and clinical characteristics
The clinical, demographic, and MRI characteristics of the study sample at baseline in HCs, RR-MS, and P-MS are summarized in Table 1 . The age, disability, and MRI differences between RR-MS and P-MS groups are representative of the respective disease courses. The distribution of oxysterol levels and baseline lipid profiles (TC, HDL-C, and LDL-C) are shown in Table 2 . Figure 1 compares the baseline oxysterol levels between HC versus MS and RR-MS versus P-MS groups. The levels of 24-HC (p = 0.015), 27-HC (p = 0.004), and 7α-HC (p < 0.001) were significantly lower in MS patients compared to HC. There were no differences in 25-HC and 7-KC levels between HC and RR-MS patients.
Associations of oxysterols with clinical factors in MS patients MS disease course.
7-KC levels were significantly higher in P-MS patients compared to RR-MS patients (p < 0.001). No differences were found between the two MS groups for 24-HC, 25-HC, 27-HC, and 7α-HC.
Disability measures. The associations of oxysterols with disability measures (MSSS and EDSS) in both RR-MS and P-MS patients were investigated (data not shown). Increased levels of 24-HC were significantly associated with MSSS (p = 0.045) in P-MS patients. There were no significant associations between any other oxysterol levels and MSSS and EDSS in the P-MS patient population. No associations were found between oxysterol levels and disability measures in RR-MS patients.
Disease-modifying therapies. We compared the levels of oxysterols between patients currently being treated with interferon and patients who are not currently being treated with interferon. The differences in 25-HC and 7α-HC levels between untreated, glatiramer acetatetreated, and interferon-treated patients are summarized in Figure 2 . We found that 25-HC (p = 0.038) and 7α-HC (p = 0.003) were significantly higher in interferontreated patients. No significant differences were observed for 24-HC, 27-HC, and 7-KC.
Associations of oxysterols with lipid profile variables
The associations between oxysterols and lipid variables (TC, HDL-C, and LDL-C), apolipoproteins (ApoA-I, ApoA-II, ApoB, and ApoE), and CRP in both HC and MS patients are summarized in Table 3 .
TC.
Higher levels of all five of the oxysterols were associated with TC for both HC and MS populations (all p < 0.001 except 27-HC in MS patients, p = 0.005).
In the HC group, 25-HC (p = 0.007) and 7α-HC (p = 0.028) were greater in subjects with borderline and high TC (TC > 200 mg/dL). MS patients with borderline and high TC had greater 24-HC (p = 0.011), 25-HC (p = 0.019), and 27-HC (p = 0.002).
LDL-C. LDL-C was associated with higher levels of 24-HC (p < 0.001), 25-HC (p = 0.024), 27-HC (p = 0.001), 7-KC (p = 0.005), and 7α-HC (p < 0.001) in HC. In MS patients, LDL-C was significantly associated with higher levels of 24-HC (p < 0.001), 25-HC (p = 0.028), 7-KC (p = 0.030), and 7α-HC (p < 0.001).
HDL-C. None of the oxysterols were significantly associated with HDL-C in either HC or MS patients. Thus, the associations of oxysterols with TC are principally driven by the associations of oxysterols with LDL-C. To further support this hypothesis, we conducted linear regression analyses that corrected for HDL-C values. The significant findings persisted.
Apolipoproteins. Apolipoproteins are functionally critical components of lipoproteins that enable physiological interactions. ApoB is the major apolipoprotein of LDL-C, whereas ApoA-I and ApoA-II are characteristic of HDL-C.
ApoB was significantly associated with increased levels of all oxysterols in both HC and MS patients (all p < 0.001), which is concordant with the LDL-C associations. ApoA-II was associated with 27-HC and 7α-HC in both HC and MS. ApoA-I was associated with 7α-HC in HC. We did not obtain evidence for associations with ApoE and CRP.
Associations of oxysterols with lipoprotein particle subclasses
To further delineate the associations between oxysterols and lipoprotein particle subclasses, we examined lipoprotein particle concentrations obtained by NMR particle sizing. The results are summarized in Table 4 .
Very low-density lipoprotein particle subclasses. Within the very low-density lipoprotein (VLDL) particle subclasses, 25-HC, 27-HC, 7-KC, and 7α-HC were associated with large and medium VLDL particle concentrations, whereas levels of 24-HC were only associated with large VLDL particle concentrations for both MS and HC.
LDL-C particle subclasses. Within the LDL particle subclasses, 25-HC, 27-HC, 7-KC, and 7α-HC were associated with small LDL particle concentrations for both MS and HC. 24-HC was associated with small LDL particle concentrations in MS but not for HC.
HDL-C particle subclasses. By comparison, associations of oxysterols with HDL particle subclass concentrations were weaker and sporadic. However, 7α-HC was associated with small HDL particle concentrations for both MS and HC.
Discussion
We investigated whether the levels of 24-HC, 25-HC, 27-HC, 7α-HC, and 7-KC differed between MS and HC and between RR-MS and P-MS, and whether the levels of these oxysterols were associated with lipid variables (HDL-C, LDL-C, TC, ApoA-I, ApoA-II, ApoB, ApoE, and CRP) and demographic variables. We found that the levels of 24-HC, 27-HC, and 7α-HC were significantly lower in MS patients compared to HC and that 7-KC levels were significantly higher in P-MS patients compared to RR-MS patients, which supports findings from previous studies. 18, 19 Additionally, oxysterol levels in both MS and HC were predominantly associated with levels of LDL-C and its cognate apolipoprotein ApoB. The large and medium VLDL and small LDL particle subclasses exhibited the strongest associations with the majority of oxysterols. 24-HC is produced exclusively in the CNS, and we hypothesize that the reduction in 24-HC levels in MS is a marker of CNS cholesterol metabolism; the decrease, therefore, reflects changes to brain cholesterol homeostasis as a result of neurodegeneration. In contrast, the reductions in 27-HC and 7α-HC observed in MS are a result of changes to cholesterol metabolism pathways in the periphery and could facilitate in pro-inflammatory changes that enable MS disease progression. The observed increases in 7-KC in P-MS compared to RR-MS reflect oxidative stress that promotes neurodegeneration in P-MS.
Results from animal models offer insights into the effector mechanisms of oxysterols. Oxysterols exert immunomodulatory effects on dendritic cell, T cell, macrophage, and B cell function via LXR and LXRindependent, EBI2-mediated signaling pathways. Oxysterols amplify and sustain inflammatory processes 20 and regulate the expression of inflammatory mediators such as interleukin (IL)-6 and matrix metalloproteinase (MMP)-9. 21, 22 LXR signaling is critical for polarization of CD4 helper T cells into Th17 cells in humans, 23 and it also potently suppresses T cell proliferation. 22, 24 LXR activation ameliorates experimental allergic encephalomyelitis (EAE), whereas LXR deficiency exacerbates it. 23 Oxysterols inhibit EAE by downregulating IL-17 production and suppressing Th17 cells. 23 Dendritic cells produce cholesterol 27 hydroxylase during EAE. 25 Thus, the reductions in 24-HC, 27-HC, and 7α-HC levels and the increases in 7-KC levels that we observed could potentially contribute to pathophysiological immune effects in MS.
There is increasing evidence for associations of cholesterol with disease progression in MS. We, 26 and others, [27] [28] [29] have shown that increased levels of LDL-C and TC are significantly associated with worsening disability on the EDSS. LDL-C and TC levels were associated with new T2 lesions and gray matter atrophy. 2 Increased levels of HDL-C and ApoA-I were associated with less BBB breakdown as assessed with surrogate CSF measures. 1 The pleiotropic effects of oxysterols on metabolic and neuroimmune processes, coupled with their ability to permeate the BBB, have generated interest in investigating the role of oxysterols in MS. 24-HC, 25-HC, and 27-HC are LXR ligands that coordinately downregulate cholesterol synthesis as well as upregulate the transporters such as the ABCA1 transporter involved in the removal of cellular cholesterol. 9 There is evidence that interferon induces 25-hydroxylase, the enzyme responsible for the conversion of cholesterol to 25-HC. 30 This may explain our finding that 25-HC was higher in interferon-treated MS patients.
7-KC is an oxidative stress marker that stimulates phenotypic changes in macrophages that promote, invasion of the vascular endothelium, and leads to secretion of inflammatory factors that can lead to the formation of MS lesions. 31 Demyelinating MS lesions have been found to contain foam cells containing ingested myelin-derived lipids. 32 Boven et al. 32 used an in vitro model of myelin ingestion to assess anti-inflammatory and pro-inflammatory markers based on location within the lesion. They found that the lipid-filled macrophages located at the center of the lesions expressed anti-inflammatory cytokines, such as IL-1ra, CCL18, IL-10, transforming growth factor (TGF)-β, and IL-4, but the cells did not express the pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, IL-1β, and IL-12p40/70, regardless of location within the lesion. 32 These authors proposed that lipid-ingested macrophages may have anti-inflammatory properties in the CNS and may also contribute to repair. They may contribute to the characteristic partial recovery that follows exacerbations in patients with RR-MS. 32 In a cross-sectional analysis, Van de Kraats et al. compared the serum and CSF levels of 24-HC, 27-HC, and lanosterol between MS patients and HC and investigated the associations with MRI measures. They found that levels of serum 24-HC were negatively associated with normalized gray matter volume (p = 0.004) in RR-MS patients. 33 Additional studies have shown that serum levels of 24-HC and 27-HC were significantly lower in MS patients compared to HC, while lanosterol levels were increased in HC relative to MS patients. 18, 19 In our analysis, we found supporting evidence that MS patients have lower levels of 24-HC and 27-HC compared to HC. Our findings indicating that age is negatively correlated with 24-HC levels in HC and that 7α-HC is lower in females compared to males are concordant with the results from a study by Stiles et al., 34 who measured an extensive panel of sterols in a multi-ethnic, population-based sample.
To further delineate the significant associations between oxysterol levels and TC, LDL-C, and ApoB, we investigated whether oxysterols were associated with particular subclasses of lipoprotein particles. To the best of our knowledge, this was the first assessment of oxysterol associations with lipoprotein particle concentrations in MS patients. We found that the large and medium VLDL and small LDL particle subclass concentrations were most significantly associated with oxysterols. These results are consistent with the cardiovascular disease literature, where previous examinations of the oxysterols in lipoproteins revealed that small dense LDL are associated with the highest levels of oxidized lipids and have the strongest pro-atherogenic effect. 35 Although we were able to investigate numerous lipid profile and clinical covariates, our study is limited by its cross-sectional design and the lack of data on statins. However, we expect the intriguing results of this study in MS will provide the rationale for wellcontrolled longitudinal studies.
In conclusion, the findings that lower levels of 24-HC, 27-HC, and 7α-HC are seen in MS patients compared to HC and that higher 7-KC levels are observed in P-MS compared to RR-MS indicate that the oxysterol network is disrupted in MS. Our findings also highlight the interdependence between oxysterols and LDL-C, which may explain the evidence that supports a role for LDL-C in the pathophysiology of MS.
